What is the recommended length for ADT in the setting of N1 disease receiving definitive radiation?

In such cases, I typically recommend two years of ADT + abiraterone based on the results of the STAMPEDE high risk localized/N+ subgroup (Attard et al., PMID 34953525). At 6 years, the addition of abiraterone led to an absolute benefit of 13% in metastasis-free survival (82% vs. 69%; HR 0.53), and a...